During his Fellowship at Johns Hopkins, Dr. Morgenthau developed clinical and research interests in sarcoidosis. Dr. Morgenthau is currently the Director of the Sarcoidosis Clinic and the Alvin S. Teirstein Sarcoidosis Support Group at the Mount Sinai Hospital. Dr. Morgenthau has published extensively on sarcoidosis. He is currently a co-investigator on a clinical trial examining new treatments in sarcoidosis.
Pulmonary Disease
MD, Sackler School of Medicine
Internship, Internal Medicine
North Shore-Long Island Jewish Health System
Residency, Internal Medicine
North Shore-Long Island Jewish Health System
Fellowship, Pulm & Critical Care
Johns Hopkins Hospital
English
Teirstein AT, Morgenthau AS. . Mt Sinai J Med 2009 Feb; 76(1): 30-36.
Morgenthau AS, Padilla ML. Spectrum of Diffuse Parenchymal Lung Disease. The Mount Sinai Journal of Medicine;.
Morgenthau AS, Iannuzzi MC. Lung Transplantation in Sarcoidosis. Minerva Pneumologica 2008 June; 47(2).
Itescu S, Atrip JH, Kwiakowski PA, Wang SF, Minanov OP, Morgenthau AS, Michler RE. Lysis of pig endothelim by IL-2 activated human natural killer cells is inhibited by swine and human major histocompatibility complex (MHC) class I gene products. Annals of Transplantation 1997; 2(1): 14-20.
Minanov OP, Itescu S, Neethling FA, Morgenthau AS, Kwiakowski P, Cooper DK, Michler RE. Anti-Gal IgG antibodies in sera of newborn humans and baboons and its significance in pig xenotransplantation. Transplantation 1997; 63(2): 182-186.
Morgenthau AS, Teirstein AS. Sarcoidosis of the Upper and Lower Airways: A Complete Review. Expert Reviews in Respiratory Medicine 2011; 5(6): 823-833.
Morgenthau AS, Iannuzzi MC. Recent Advances in Sarcoidosis. Chest 2011; 139(1): 174-182.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Morgenthau did not report having any of the following types of financial relationships with industry during 2015 and/or 2016: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website.
Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.